[go: up one dir, main page]

PE20141159A1 - Metodos para tratar o prevenir trastornos relacionados con el colesterol - Google Patents

Metodos para tratar o prevenir trastornos relacionados con el colesterol

Info

Publication number
PE20141159A1
PE20141159A1 PE2013002471A PE2013002471A PE20141159A1 PE 20141159 A1 PE20141159 A1 PE 20141159A1 PE 2013002471 A PE2013002471 A PE 2013002471A PE 2013002471 A PE2013002471 A PE 2013002471A PE 20141159 A1 PE20141159 A1 PE 20141159A1
Authority
PE
Peru
Prior art keywords
sec
monoclonal antibody
amount
methods
related disorders
Prior art date
Application number
PE2013002471A
Other languages
English (en)
Inventor
Timothy David Osslund
Christi L Clogston
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46124771&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141159(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PE20141159A1 publication Critical patent/PE20141159A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMULACION ESTABLE QUE COMPRENDE: a) UN ANTICUERPO MONOCLONAL QUE SE UNE ESPECIFICAMENTE A PCSK9, EN DONDE PCSK9 COMPRENDE LOS AMINOACIDOS DE SEC. ID. N�:1, EL ANTICUERPO MONOCLONAL EN UNA CANTIDAD DE ENTRE 40 MG/ML Y 300MG/ML; b) UN TAMPON FARMACEUTICAMENTE ACEPTABLE EN UNA CANTIDAD DE 0,05 mM - 40 mM, QUE SE SELECCIONA DE GLUTAMATO, FOSFATO, CITRATO DE SODIO, ENTRE OTROS; c) UN SURFACTANTE EN UNA CANTIDAD DE 0,01%P/V-20%P/V, QUE SE SELECCIONA DE POLISORBATO 80, POLISOBATO 20; d) UN ESTABILIZADOR FARMACEUTICAMENTE ACEPTABLE QUE SE SELECCIONA DE UN DISACARIDO, POLIOL, PROLINA, ENTRE OTROS; EN CANTIDADES DE 0,5%P/V Y 10% P/V. EN DONDE LA FORMULACION ESTABLE TIENE UN PH DE 4,0- 6,0. DICHO ANTICUERPO MONOCLONAL SE SELECCIONA DEL GRUPO QUE CONSISTE EN 21B12, 11F1, 31H4, 8 A3 Y 8 A1, ADEMAS PRESENTA UNA REGION VARIABLE DE CADENA LIGERA QUE COMPRENDE SEC. ID N�: 23, SEC. ID N�: 465, ENTRE OTROS Y UNA REGION VARIABLE DE CADENA PESADA QUE COMPRENDE SEC. ID. N�: 49, SEC. ID N�: 463, ENTRE OTROS. SE REFIERE TAMBIEN A METODOS PARA PRODUCIR DICHA FORMULACION QUE SON UTILES PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON EL COLESTEROL.
PE2013002471A 2011-05-10 2012-05-10 Metodos para tratar o prevenir trastornos relacionados con el colesterol PE20141159A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161484610P 2011-05-10 2011-05-10
US201161562303P 2011-11-21 2011-11-21
US201261595526P 2012-02-06 2012-02-06
US201261614417P 2012-03-22 2012-03-22
US201261642363P 2012-05-03 2012-05-03

Publications (1)

Publication Number Publication Date
PE20141159A1 true PE20141159A1 (es) 2014-09-19

Family

ID=46124771

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2023003011A PE20240547A1 (es) 2011-05-10 2012-05-10 Metodos para tratar o prevenir trastornos relacionados con el colesterol
PE2013002471A PE20141159A1 (es) 2011-05-10 2012-05-10 Metodos para tratar o prevenir trastornos relacionados con el colesterol
PE2018001494A PE20181790A1 (es) 2011-05-10 2012-05-10 Metodos para tratar o prevenir trastornos relacionados con el colesterol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2023003011A PE20240547A1 (es) 2011-05-10 2012-05-10 Metodos para tratar o prevenir trastornos relacionados con el colesterol

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2018001494A PE20181790A1 (es) 2011-05-10 2012-05-10 Metodos para tratar o prevenir trastornos relacionados con el colesterol

Country Status (36)

Country Link
US (1) US20210047434A1 (es)
EP (2) EP2707029B1 (es)
JP (3) JP6166717B2 (es)
KR (5) KR20250127346A (es)
CN (3) CN107261139A (es)
AP (1) AP2013007303A0 (es)
AR (1) AR086344A1 (es)
AU (5) AU2012253434B2 (es)
CA (1) CA2835294C (es)
CL (2) CL2013003214A1 (es)
CR (1) CR20130640A (es)
CY (1) CY1122967T1 (es)
DK (1) DK2707029T3 (es)
EA (1) EA031228B1 (es)
ES (1) ES2781749T3 (es)
HR (1) HRP20200545T1 (es)
HU (1) HUE049018T2 (es)
IL (4) IL311262B2 (es)
JO (2) JOP20200043A1 (es)
LT (1) LT2707029T (es)
ME (1) ME03765B (es)
MX (2) MX378241B (es)
MY (2) MY173860A (es)
PE (3) PE20240547A1 (es)
PH (2) PH12013502287A1 (es)
PL (1) PL2707029T3 (es)
PT (1) PT2707029T (es)
RS (1) RS60292B1 (es)
SG (1) SG194855A1 (es)
SI (1) SI2707029T1 (es)
SM (1) SMT202000183T1 (es)
TW (5) TWI610683B (es)
UA (2) UA114602C2 (es)
UY (1) UY34063A (es)
WO (1) WO2012154999A1 (es)
ZA (1) ZA201309173B (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
PH12013501576A1 (en) 2011-01-28 2013-09-30 Sanofi Biotechnology Pharmaceutical compositions comprising human antibodies to pcsk9
AU2012282130B2 (en) * 2011-07-14 2017-06-22 Pfizer Inc. Treatment with anti-PCSK9 antibodies
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
CA2848201C (en) 2011-09-16 2020-10-27 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
KR20150023711A (ko) 2012-06-15 2015-03-05 제넨테크, 인크. 항-pcsk9 항체, 제제, 투여, 및 사용 방법
JP6309521B2 (ja) 2012-08-13 2018-04-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ｐＨ依存性結合特性を有する抗ＰＣＳＫ９抗体
US20160032014A1 (en) * 2013-03-15 2016-02-04 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
GB2523527A (en) * 2013-04-05 2015-09-02 Weiming Xu Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9)
TWI679019B (zh) * 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
US10111953B2 (en) * 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
JP2016523847A (ja) 2013-06-07 2016-08-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｐｃｓｋ９のインヒビターの投与によりアテローム性動脈硬化を阻害する方法
JP6267792B2 (ja) * 2013-06-28 2018-01-24 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
MX2016006226A (es) * 2013-11-12 2016-09-07 Sanofi Biotechnology Regimenes de dosificacion para uso con inhibidores de pcsk9.
MX2016006583A (es) * 2013-11-20 2016-09-06 Cymabay Therapeutics Inc Tratamiento de hipercolesterolemia familiar homocigotica.
WO2015092394A1 (en) * 2013-12-17 2015-06-25 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
EP2975058A1 (en) * 2014-07-15 2016-01-20 Kymab Limited Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
TWI713444B (zh) * 2013-12-17 2020-12-21 英商凱美寶有限公司 人類標靶
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
EP2886558A1 (en) * 2013-12-17 2015-06-24 Kymab Limited Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
CN106062004A (zh) * 2013-12-17 2016-10-26 科马布有限公司 人靶标
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
WO2015127273A1 (en) * 2014-02-21 2015-08-27 Medimmune, Llc Anti-pcsk9~glp-1 fusions and methods for use
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP4403213A3 (en) * 2014-03-17 2024-10-23 Sanofi Biotechnology Methods for reducing cardiovascular risk
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US9486428B2 (en) 2014-03-20 2016-11-08 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
JP6865038B2 (ja) 2014-04-11 2021-04-28 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｎａｆｌｄおよびｎａｓｈの治療
EP3929218A1 (en) 2014-07-14 2021-12-29 Amgen, Inc Crystalline antibody formulations
EP3169710A1 (en) 2014-07-14 2017-05-24 Amgen Inc. Crystalline antibody formulations
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
EP3332790A1 (en) * 2014-07-15 2018-06-13 Kymab Limited Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
EP4328245A3 (en) * 2014-07-15 2024-06-05 Kymab Ltd. Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
JP6912374B2 (ja) * 2014-07-16 2021-08-04 サノフィ・バイオテクノロジー 高コレステロール血症を有する高心血管リスク患者を処置するための方法
CA2955294A1 (en) 2014-07-16 2016-01-21 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
CA2964470A1 (en) * 2014-10-17 2016-04-21 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
ES2964713T3 (es) 2014-10-23 2024-04-09 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CN107660149B (zh) * 2015-04-21 2021-04-27 舒泰神（北京）生物制药股份有限公司 一种神经生长因子组合物及注射粉剂
US20170044516A1 (en) 2015-08-11 2017-02-16 Industrial Technology Research Institute Biochemistry reactive material and device for eliminating electronegative low-density lipoprotein (ldl) and method for treating blood or plasma ex vivo to eliminate electronegative low-density lipoprotein therein
CA2995645A1 (en) 2015-08-18 2017-02-23 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
CN106810609A (zh) 2015-11-27 2017-06-09 苏州君盟生物医药科技有限公司 抗pcsk9抗体及其应用
RU2739208C2 (ru) * 2015-12-31 2020-12-21 Цзянсу Хэнжуй Медицин Ко., Лтд. Анти-pcsk9 антитело, его антигенсвязывающий фрагмент и их медицинское применение
US20200270365A1 (en) 2016-01-05 2020-08-27 Jiangsu Hengrui Medicine Co., Ltd. Pcsk9 antibody, antigen-binding fragment thereof, and medical uses thereof
GB201608323D0 (en) * 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
WO2017200715A1 (en) * 2016-05-19 2017-11-23 Cymabay Therapeutics, Inc. Treatment of severe hyperlipidemia
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
KR102806206B1 (ko) 2016-09-29 2025-05-13 암젠 인크 저-점도 항원 결합 단백질 및 이의 제조 방법
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JOP20190112A1 (ar) * 2016-11-14 2019-05-14 Amgen Inc علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
CN108239150A (zh) 2016-12-24 2018-07-03 信达生物制药(苏州)有限公司 抗pcsk9抗体及其用途
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
AU2018229724B2 (en) * 2017-03-06 2025-04-03 Merck Patent Gmbh Aqueous anti-PD-L1 antibody formulation
US11325945B2 (en) 2017-04-12 2022-05-10 Cadila Healthcare Limited Peptide based PCSK9 vaccine
CA3067953A1 (en) * 2017-06-30 2019-01-03 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition comprising pcsk-9 antibody and use thereof
JP6639463B2 (ja) * 2017-12-21 2020-02-05 アムジエン・インコーポレーテツド ホモ接合性家族性高コレステロール血症の治療方法
CN110464842B (zh) * 2018-05-11 2022-10-14 信达生物制药(苏州)有限公司 包含抗pcsk9抗体的制剂及其用途
CA3110346A1 (en) * 2018-08-24 2020-02-27 Esperion Therapeutics, Inc. Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses
FI3911648T3 (fi) 2019-01-18 2025-01-10 Astrazeneca Ab 6'-[[[(1s,3s)-3-[[5-(difluorometoksi)-2-pyrimidinyyli]amino]syklopentyyli]amino][1(2h),3'-bipyridin]-2-oni pcsk9:n estäjänä ja menetelmät sen käyttöön
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2023286766A1 (ja) * 2021-07-13 2023-01-19 浩志 貴田 抗体と遺伝子に結合能を有するポリペプチド
CN114438075A (zh) * 2022-02-25 2022-05-06 刘博巽 一种枯草芽孢杆菌前蛋白酶9靶向结合蛋白的筛选方法与应用
WO2024002357A1 (zh) * 2022-06-30 2024-01-04 康融东方（广东）医药有限公司 抗pcsk9抗体的制剂及其应用
CN116983434B (zh) * 2023-09-28 2024-03-15 康霖生物科技（杭州）有限公司 用于基因治疗的核酸构建体及其用途

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3180193A (en) 1963-02-25 1965-04-27 Benedict David Machines for cutting lengths of strip material
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
JPS58166633A (ja) 1982-03-29 1983-10-01 Toshiba Corp 有機溶媒電池用正極
JPS58166634A (ja) 1982-03-29 1983-10-01 Toshiba Corp 有機溶媒電池用正極
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
JPS62170639A (ja) 1986-01-22 1987-07-27 株式会社システムメンテナンス 防蟻板の取付け工法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
FR2664073A1 (fr) 1990-06-29 1992-01-03 Thomson Csf Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP0648265A4 (en) 1992-06-18 1996-12-04 Genpharm Int PROCESS FOR THE PRODUCTION OF NON-HUMAN TRANSGENIC ANIMALS HAVING AN ARTIFICIAL YEAST CHROMOSOME.
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
KR100308764B1 (ko) 1995-08-29 2001-12-17 마나배게이사꾸 키메라동물및그의제작법
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
JP2003533187A (ja) 2000-05-03 2003-11-11 アムジエン・インコーポレーテツド 治療薬としてのＦｃドメインを含む修飾ペプチド
JP5078217B2 (ja) * 2001-11-14 2012-11-21 デュレクト コーポレーション 注入可能なデポー組成物およびそれらの使用
CN1897918A (zh) * 2003-11-17 2007-01-17 阿尔萨公司 包含两亲性分子作为混悬载体的组合物和剂型
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
PE20081610A1 (es) * 2007-01-09 2008-12-09 Wyeth Corp Formulaciones de anticuerpos anti-il-13 y usos de los mismos
EP2068923A4 (en) * 2007-03-30 2010-11-24 Medimmune Llc ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
CA2703712A1 (en) * 2007-10-26 2009-04-30 Joseph A. Hedrick Anti-pcsk9 and methods for treating lipid and cholesterol disorders
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
MX345226B (es) * 2008-10-29 2017-01-20 Ablynx Nv Formulaciones de moleculas de union a antigeno de dominio sencillo.
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
WO2011028938A1 (en) * 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
JP5743234B2 (ja) * 2010-01-15 2015-07-01 キリン−アムジェン・インコーポレーテッド 抗体製剤及び治療レジメン
WO2011109415A2 (en) * 2010-03-02 2011-09-09 Amgen Inc. Reducing viscosity of pharmaceutical formulations
JP5782185B2 (ja) 2012-06-01 2015-09-24 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
JP6071725B2 (ja) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 電気自動車の駆動力制御装置
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
US11284893B2 (en) 2019-04-02 2022-03-29 Covidien Lp Stapling device with articulating tool assembly

Also Published As

Publication number Publication date
IL229276A0 (en) 2014-01-30
AU2020201219B2 (en) 2022-05-12
WO2012154999A1 (en) 2012-11-15
MY198324A (en) 2023-08-24
CN103841992A (zh) 2014-06-04
JP2017160208A (ja) 2017-09-14
IL311262A (en) 2024-05-01
KR20230066480A (ko) 2023-05-15
AU2025234149A1 (en) 2025-10-09
SG194855A1 (en) 2013-12-30
AU2017232084A1 (en) 2017-10-12
JO3520B1 (ar) 2020-07-05
TWI705826B (zh) 2020-10-01
KR20210109675A (ko) 2021-09-06
RS60292B1 (sr) 2020-07-31
JOP20200043A1 (ar) 2017-06-16
AU2012253434A1 (en) 2013-12-19
PH12019501274A1 (en) 2020-09-14
EP3597218A1 (en) 2020-01-22
AU2012253434B2 (en) 2017-07-06
NZ734570A (en) 2021-11-26
EA031228B1 (ru) 2018-12-28
AP2013007303A0 (en) 2013-12-31
MX2019004264A (es) 2021-12-08
US20130064825A1 (en) 2013-03-14
LT2707029T (lt) 2020-07-10
NZ618300A (en) 2016-04-29
TW202417041A (zh) 2024-05-01
HRP20200545T1 (hr) 2020-10-02
UA126229C2 (uk) 2022-09-07
PE20181790A1 (es) 2018-11-15
PH12013502287A1 (en) 2014-02-10
IL311262B1 (en) 2025-07-01
UA114602C2 (uk) 2017-07-10
JP6400768B2 (ja) 2018-10-03
IL288048B2 (en) 2024-09-01
AU2022215259A1 (en) 2022-09-29
CA2835294A1 (en) 2012-11-15
PL2707029T3 (pl) 2020-07-27
KR102132496B1 (ko) 2020-07-09
TWI877669B (zh) 2025-03-21
KR20250127346A (ko) 2025-08-26
PT2707029T (pt) 2020-04-22
KR102528752B1 (ko) 2023-05-08
ES2781749T3 (es) 2020-09-07
EP2707029B1 (en) 2020-01-15
TWI610683B (zh) 2018-01-11
IL288048A (en) 2022-01-01
ME03765B (me) 2021-04-20
US20210047434A1 (en) 2021-02-18
PE20240547A1 (es) 2024-03-19
IL229276B (en) 2021-03-25
IL281178B (en) 2021-12-01
MX378241B (es) 2025-03-04
TW202108172A (zh) 2021-03-01
EA201391668A1 (ru) 2014-06-30
CN107261139A (zh) 2017-10-20
BR112013028819A2 (pt) 2017-01-31
IL311262B2 (en) 2025-11-01
TWI809272B (zh) 2023-07-21
MX2013013187A (es) 2014-03-21
JP2014516953A (ja) 2014-07-17
SMT202000183T1 (it) 2020-05-08
HUE049018T2 (hu) 2020-08-28
JP2018199717A (ja) 2018-12-20
KR20140031938A (ko) 2014-03-13
NZ717550A (en) 2021-08-27
IL281178A (en) 2021-04-29
KR20200086745A (ko) 2020-07-17
AU2020201219A1 (en) 2020-03-12
JP6166717B2 (ja) 2017-07-19
ZA201309173B (en) 2021-05-26
AR086344A1 (es) 2013-12-04
CN113786482A (zh) 2021-12-14
CA2835294C (en) 2023-09-19
UY34063A (es) 2012-11-30
TW201811367A (zh) 2018-04-01
DK2707029T3 (da) 2020-03-30
AU2017232084B2 (en) 2019-11-21
CY1122967T1 (el) 2021-10-29
JP6599527B2 (ja) 2019-10-30
SI2707029T1 (sl) 2020-08-31
TWI609695B (zh) 2018-01-01
TW201306865A (zh) 2013-02-16
TW201536323A (zh) 2015-10-01
IL288048B1 (en) 2024-05-01
CL2017003288A1 (es) 2018-04-27
EP2707029A1 (en) 2014-03-19
CR20130640A (es) 2014-01-14
CL2013003214A1 (es) 2014-06-20
MY173860A (en) 2020-02-25
CN103841992B (zh) 2021-08-13

Similar Documents

Publication Publication Date Title
PE20141159A1 (es) Metodos para tratar o prevenir trastornos relacionados con el colesterol
BRPI0713421A2 (pt) Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
AR067011A1 (es) Formulaciones de anticuerpos
EA202191559A1 (ru) Модифицированные аминовые липиды
PE20190469A1 (es) Formulaciones, kits y metodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados
NZ719036A (en) Anti-pdl1 antibody formulations
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
MY200833A (en) Antibody-Containing Preparation
MX362382B (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
AR105313A1 (es) Anticuerpo anti-cd137 terapéutico
AR107014A1 (es) Formulación farmacéutica acuosa
AR089787A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-ang2
MY159156A (en) Antibody formulation
AR075715A1 (es) Formulacion de anticuerpo liofilizado
PE20131324A1 (es) Formulacion subcutanea de anticuerpo anti-her2
CO6650415A2 (es) Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa
TN2009000382A1 (en) Stable antibody formulations
PE20141265A1 (es) Formulaciones liofilizadas de fgf-18
PE20170900A1 (es) Metodos y formulaciones para tratar enfermedades vasculares de los ojos
PE20190405A1 (es) FORMULACION PARA ANTICUERPO ANTI-alfa4beta7
MY197773A (en) Highly concentrated pharmaceutical formulations comprising anti-cd20 antibody
MA34172B1 (fr) Anticorps bispécifiques, bivalents anti-vegf/anti-ang-2
EA201201309A1 (ru) Фармацевтически активные производные двузамещенного триазина
AR071852A1 (es) Formulacion farmaceutica de un anticuerpo frente a ox40l
PE20061043A1 (es) Composicion farmaceutica que comprende anticuerpos monoclonales

Legal Events

Date Code Title Description
FC Refusal